Immunosuppression or immunodeficiency, including a history of primary or acquired immunodeficiency states (eg, leukemia, lymphoma or other malignant neoplasms affecting bone marrow or lymphatic system, AIDS or other clinical manifestations of infection with HIV); patients receiving immunosuppressive therapy; women who are pregnant or may become pregnant during or within 3 months of treatment; history of anaphylactic/anaphylactoid reaction to gelatin, neomycin (excluding contact dermatitis to neomycin), or any component of the vaccine.
The risk of live zoster vaccine–induced adverse reactions may be increased by coadministration of antineoplastic agents. Administration of live zoster vaccine to patients who are receiving antineoplastic agents should be deferred.
Zoster vaccine is a live vaccine and the risk of disseminated disease is greater in patients who are immunosuppressed. Coadministration is contraindicated.
Pneumococcal vaccine polyvalent
A reduced response to live zoster vaccine has been observed in individuals who received these vaccines concurrently compared with those who received these vaccines 4 wk apart. Administer the vaccines at least 4 wk apart.